Measuring pulse wave velocity and blood pressure using a new device
Photoplethysmographic Measurements of Pulse Wave Velocity (PWV) and Blood Pressure (BP) MEPPAVOP
This study is testing a new device that uses light to measure blood pressure and pulse wave speed in healthy adults to see if it can provide a more accurate and comfortable way to check for high blood pressure.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 27 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | University Hospital, Grenoble Academic / other |
| Locations | 1 site (Grenoble) |
| Trial ID | NCT05393401 on ClinicalTrials.gov |
What this trial studies
This study aims to evaluate a prototype device that uses photoplethysmography to continuously monitor pulse wave velocity (PWV) and its correlation with blood pressure (BP) in healthy volunteers. The device, known as VOP1k, is designed to provide a non-invasive alternative to traditional BP measurement techniques, which can be prone to errors and discomfort. By analyzing the relationship between PWV and BP, the study seeks to improve the accuracy of hypertension diagnosis and monitoring. Healthy volunteers aged 18 and over will participate in the trial, which will help assess the device's effectiveness and reliability.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy volunteers aged 18 and older who can provide informed consent.
Not a fit: Patients with chronic illnesses, active implants, or specific cardiovascular conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this device could lead to more accurate and comfortable blood pressure monitoring, improving hypertension diagnosis and management.
How similar studies have performed: While the approach of using photoplethysmography for PWV measurement is established, the specific application of this prototype device is novel and has not been extensively tested in similar studies.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Healthy healthy volunteer subject, * Aged 18 or over, * Having expressed their consent to the research, * Affiliated to a social security scheme, * Registered in the national file of people who lend themselves to biomedical research Exclusion Criteria: * People referred to in Articles L1121-5 to L1121-8 of the Public Health Code (corresponds to all protected persons: pregnant, parturient or breastfeeding women, persons deprived of liberty by judicial or administrative decision, persons subject of psychiatric care, minor, and person subject to a legal protection measure: guardianship, curatorship or safeguard of justice) * Any history or presence of chronic illness * Presence of Wolf Parkinson White ECG changes * Subject with orthostatic hypotension * People with an active implant (e.g. pacemaker) * Known allergy or intolerance to silicone * Orthostatic hypotension * Cutaneous excoriations preventing the placement of sensors on the arms * Patient with an active implant * Subject cannot be contacted in case of emergency * Taking treatment that may impact the recorded physiological measurements * Subject in period of exclusion from another clinical investigation * Subject who would receive more than 4500 euros in compensation due to his participation in other biomedical research in the 12 months preceding this study
Where this trial is running
Grenoble
- Clinatec Cea/Chuga — Grenoble, France (Recruiting)
Study contacts
- Study coordinator: Daniel ANGLADE, MD, PhD
- Email: danglade@chu-grenoble.fr
- Phone: 04 38 78 17 46
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.